Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Rob Jones

- PMLiVE

Will biosimilars ever catch on in the US?

Why biosimilars are viewed in the US as ‘me too’ drugs rather than as just-as-good alternatives to branded products

- PMLiVE

Lucid Learning and Development

Julianne Tate, Head of Learning and Development at Lucid Group, discusses the new programmes and tools that she has been busy developing and rolling out throughout the Group — Elevating...

Lucid Group Communications Limited

- PMLiVE

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

The role of medical affairs in positive and appropriate engagement with patient advocacy groups

Written by Gavin Jones, Dr Alexandra Safronova & Professor Peter Rutherford, OPEN Health

OPEN Health

- PMLiVE

J&J begins search for a coronavirus vaccine as confirmed cases rise

Death toll has now reached 170, with 7,711 confirmed cases in China

Sanofi reception

Sanofi’s rare disease drug olipudase alfa scores in late-stage study

Met crucial endpoints across two clinical studies

- PMLiVE

J&J gets EMA nod for wider use of Erleada in prostate cancer

Maintains a regulatory lead over rival Xtandi

- PMLiVE

New faces at Synergy Vision, Makara Health and JPA Health

The latest movers in healthcare comms

- PMLiVE

Policy and public health: patient preferences

When selecting a healthcare provider, what patients are looking for can reveal a lot

OPEN Health’s response to the FDA’s guidance on long term follow up post gene therapy

Written by Gavin Jones, OPEN Health

OPEN Health

- PMLiVE

Four Comms restructures, reveals 2019 revenue growth and acquisition plan

Four Communications has undergone a restructure, with 17 practices reorganised into seven business units - as the firm reveals that revenue grew eight per cent in 2019. It is also...

Four Agency Worldwide

- PMLiVE

Vyndaqel a bright spot as Pfizer comes under pressure

Faces a challenging period as big brands experience a slowdown

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links